Table 2. Treatment for Recurrent Disease Prior to Bevacizumab.

Patient No.	No. prior recurrences	Sites of recurrence	Prior chemotherapy regimens (response)	Prior hormonal and targeted therapy	Prior RT	No. Prior surgeries
1	7	Pelvis; Liver	Carboplatin/paclitaxel (CR), BEP (PR), etoposide (P), liposomal doxorubicin (PR), gemcitabine (P), topotecan (P)	Leuprolide acetate, tamoxifen, megestrol acetate, anastrozole	No	4
2	1	Abdomen, pelvis	Carboplatin/paclitaxel (PR)	None	Yes	No
3	4	Left ovary, pelvis, abdomen, Liver	Carboplatin/paclitaxel (CR), carboplatin/paclitaxel (PR), docetaxel (S), liposomal doxorubicin (P)	Leuprolide acetate, imatinib mesylate	No	4
4	4	Abdomen, pelvis, liver, spleen, lung	Intraperitoneal mitomycin C and VAC (CR), carboplatin/paclitaxel (CR), liposomal doxorubicin (S), tegafur-uracil (P), carboplatin/docetaxel (S)	Leuprolide acetate, anastrozole, megestrol acetate, anastrozole, gefitinib	Yes	4
5	4	Abdomen, pelvis, retroperitoneum, liver	BEP (CR), cisplatin (NT), carboplatin (CR)	Anastrozole, leuprolide acetate, erlotinib, tamoxifen	No	3
6	2	Pelvis, rectosigmoid	Carboplatin/paclitaxel (CR)	Tamoxifen	Yes	1
7	6	Abdomen, pelvis, liver	BEP (CR), carboplatin/docetaxel (PR)	Leuprolide acetate, anastrozole	No	4
8	1	Uterus, omentum, pelvis, liver	BEP (P), carboplatin/paclitaxel (P), etoposide/ifosfamide (P), liposomal doxorubicin/vinorelbine/gemcitabine (P)	None	Yes	1

RT: radiotherapy; CR: complete response; BEP: bleomycin/etoposide/cisplatin; PR: partial response; P: progression; S: stable; VAC: vincristine/actinomycin D/cyclophosphamide; NT: did not tolerate chemotherapy